Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
Entera Bio Ltd. (NASDAQ: ENTX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 3:30 PM ET. The company's CEO, Miranda Toledano, will present and hold one-on-one meetings during the event. Entera specializes in developing orally delivered peptides and therapeutic proteins, focusing on addressing unmet medical needs where injectable therapies face challenges. Their advanced products include EB613 for osteoporosis and EB612 for hypoparathyroidism, with a Phase 2 study recently completed for EB613.
- None.
- None.
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference.
| Presentation Date: | Wednesday, September 14, 2022 |
| Time: | 3:30 PM ET |
| Presenter: | Miranda Toledano - CEO |
| Conference Website | https://hcwevents.com/globalconference/ |
About Entera Bio
Entera is a leader in the development of orally delivered macromolecules therapeutics including peptides and other therapeutic proteins, for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The Company recently completed the phase 2 study for EB613 and has a Type C meeting scheduled with FDA with respect to its Phase 3 program in H2 2022. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.
FAQ
When is Entera Bio's presentation at the H.C. Wainwright Conference?
Who will represent Entera Bio at the investment conference?
What is Entera Bio's focus in drug development?
What advanced products is Entera Bio currently developing?
What stage is the clinical development of EB613?
Does Entera Bio collaborate with other companies?
